Chart Of The Day- Biocon Back In Flavour

Biocon surged over 14% as investors thronged to buy the stock after it received USFDA approval for its biosimilar of cancer drug. The stock gapped-up 10% on 13x the average trading value. As a result of today’s move, the stock recorded a new all-time high and flagged a power from pivot.

Biocon_MarketSmithIndia